Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.

Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA.

Acta Ophthalmol. 2012 Mar;90(2):146-54. doi: 10.1111/j.1755-3768.2009.01857.x. Epub 2010 Aug 20.

2.

The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.

Holmstrom S, Buchholz P, Walt J, Wickstrøm J, Aagren M.

Curr Med Res Opin. 2006 May;22(5):897-905.

PMID:
16709311
3.

Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.

Kobelt G, Jönsson L, Gerdtham U, Krieglstein GK.

Graefes Arch Clin Exp Ophthalmol. 1998 Nov;236(11):811-21.

PMID:
9825256
4.
6.

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.

Rouland JF, Le Pen C, Benhaddi H, Piriou E, Lilliu H, Kenigsberg PA; Glaucoma Study Group..

Eur J Ophthalmol. 2005 Sep-Oct;15(5):562-80.

PMID:
16167287
7.

Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.

Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, Aballéa S.

Eur J Ophthalmol. 2003 Jul;13 Suppl 4:S30-43.

PMID:
12948051
8.

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Payet S, Denis P, Berdeaux G, Launois R.

Clin Drug Investig. 2008;28(3):183-98.

PMID:
18266403
10.

Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.

Olander K, Zimmerman TJ, Downes N, Schoenfelder J; Xalacom/Latanoprost Study Group..

Clin Ther. 2004 Oct;26(10):1619-29.

PMID:
15598478
15.

Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.

Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, Gandolfo E.

Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2917-23.

PMID:
16799034
16.
17.

Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.

Lesk MR, Koulis T, Sampalis F, Sampalis JS, Bastien NR.

Ann Pharmacother. 2008 Apr;42(4):498-504. doi: 10.1345/aph.1K565. Epub 2008 Mar 25.

PMID:
18364402
18.

Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.

Katz LJ, Rauchman SH, Cottingham AJ Jr, Simmons ST, Williams JM, Schiffman RM, Hollander DA.

Curr Med Res Opin. 2012 May;28(5):781-8. doi: 10.1185/03007995.2012.681036. Epub 2012 Apr 25.

PMID:
22458918
19.

Latanoprost : an update of its use in glaucoma and ocular hypertension.

Perry CM, McGavin JK, Culy CR, Ibbotson T.

Drugs Aging. 2003;20(8):597-630. Review.

PMID:
12795627
20.

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.

Rouland JF, Le Pen C; Ophthalmologists of the Glaucoma Study..

Eur J Ophthalmol. 2003 Jul;13 Suppl 4:S5-20.

PMID:
12948049

Supplemental Content

Support Center